| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $...
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the li...
Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $...
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.82) per share which missed the analyst consensus estimate...
Goldman Sachs analyst Corinne Jenkins maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target ...
Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price ta...